Articles

BRAF + MEK Inhibitors in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

BRAF Inhibitor + Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

Second-Line Therapies in KRAS–Wild-Type mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer

A New Predictive Biomarker for Cetuximab—The New EPOC Trial

ASCO 2014 – Colorectal and Head & Neck Cancer

Pidilizumab in Relapsed Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Nivolumab in Chemotherapy-Naïve Advanced NSCLC

ASCO 2014 – Immuno-Oncology

Blinatumomab in Relapsed/Refractory Acute Lymphoblastic Leukemia

ASCO 2014 – Immuno-Oncology

Adoptive T-Cell Therapy for Cervical Cancer

ASCO 2014 – Immuno-Oncology

Pembrolizumab (MK-3745) in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology

Page 146 of 147